Mad Money Mailbag: Stem Your Stem Cell Enthusiasm

Cramer isn't thrilled about this cash-burning group, but finds one he can smile at.
Author:
Publish date:

Editor's Note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EDT on CNBC.

What companies might be in a position to lead the way in stem-cell research?-- Craig from New York

James J. Cramer:

Stem-cell research is a dicey area to invest in. None of the companies have any real profits yet, and most are burning cash at a high rate. If I had to choose one, it would be

Geron

(GERN) - Get Report

. The company has more than 200 patents, and a decent balance sheet. I'd wait to buy it on a pullback, though, because it has had a nice run.

What is your take on Chesapeake (CHK) - Get Report?-- Eric from Maine

James J. Cramer:

I believe Chesapeake is a good company. Management has been actively buying the stock in the open market, and that speaks strongly to me about the strength of the underlying fundamentals in the energy space.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

. Learn how to become a better investor. Get started now with the investing rules that Cramer lays out: